Drug Detail:Dexrazoxane (Dexrazoxane [ dex-ray-zox-ane ])
Drug Class: Miscellaneous uncategorized agents
Usual Adult Dose for Cardiomyopathy Prophylaxis
Zinecard (R):
Dosage ratio of dexrazoxane to doxorubicin is 10:1 (e.g. 500 mg/m2 dexrazoxane to 50 mg/m2 doxorubicin)
- Administer via IV infusion over 15 minutes.
- DO NOT administer via IV push.
- Administer doxorubicin within 30 minutes of completion of dexrazoxane infusion; do not administer doxorubicin before dexrazoxane.
Comments:
- Do not use with the initiation of doxorubicin therapy.
Use(s): Reducing incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m2 and who will continue to receive doxorubicin.
Usual Adult Dose for Extravasation
Totect (R):
Recommended doses:
Day one: 1000 mg/m2 IV over 1 to 2 hours
Day two: 1000 mg/m2 IV over 1 to 2 hours
Day three: 500 mg/m2 IV over 1 to 2 hours
Maximum doses:
Day one: 2000 mg
Day two: 2000 mg
Day three: 1000 mg
Comments:
- Product must be diluted with 50 mL of 0.167 M sodium lactate injection solution prior to administration.
- Initiate first infusion as soon as possible and within the first 6 hours of extravasation.
- Start day 2 and 3 treatments at the same hour as the first day (give or take 3 hours).
- Remove cooling features such as ice packs (if used) at least 15 minutes before administration to allow sufficient blood flow to extravasation area.
Use(s): Extravasation resulting from intravenous anthracycline chemotherapy
Renal Dose Adjustments
CrCl under 40 mL/min: Reduce dose by half
Liver Dose Adjustments
Extravasation: Not recommended in hepatic impairment.
- Perform routing liver function tests before each administration if patient has known liver function disorders.
Cardiomyopathy prophylaxis: Since doxorubicin dose reduction is recommended, reduce dose of dexrazoxane proportionally (maintaining the 10:1 ratio).
Precautions
CONTRAINDICATIONS:
- Do not use with non-anthracycline chemotherapy regimens.
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available